LU92759I2 - Vorapaxar ou son sel solvat pharmacologiquement admissible - Google Patents
Vorapaxar ou son sel solvat pharmacologiquement admissible Download PDFInfo
- Publication number
- LU92759I2 LU92759I2 LU92759C LU92759C LU92759I2 LU 92759 I2 LU92759 I2 LU 92759I2 LU 92759 C LU92759 C LU 92759C LU 92759 C LU92759 C LU 92759C LU 92759 I2 LU92759 I2 LU 92759I2
- Authority
- LU
- Luxembourg
- Prior art keywords
- pharmacologiquement
- solvat
- vorapaxar
- admissible
- son sel
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37307202P | 2002-04-16 | 2002-04-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
LU92759I2 true LU92759I2 (en) | 2015-08-31 |
Family
ID=29250954
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU92759C LU92759I2 (en) | 2002-04-16 | 2015-06-29 | Vorapaxar ou son sel solvat pharmacologiquement admissible |
Country Status (34)
Country | Link |
---|---|
US (3) | US7304078B2 (es) |
EP (5) | EP1495018B3 (es) |
JP (2) | JP4558331B2 (es) |
KR (1) | KR101026929B1 (es) |
CN (1) | CN1659162B (es) |
AR (1) | AR039570A1 (es) |
AT (3) | ATE378330T1 (es) |
AU (1) | AU2003221932B2 (es) |
BR (1) | BRPI0309309B8 (es) |
CA (1) | CA2482858C (es) |
CY (3) | CY1107184T1 (es) |
DE (3) | DE60317493T3 (es) |
DK (2) | DK2065384T3 (es) |
EC (1) | ECSP045368A (es) |
ES (3) | ES2357876T3 (es) |
FR (1) | FR15C0047I2 (es) |
HK (3) | HK1070887A1 (es) |
IL (1) | IL164585A (es) |
LT (1) | LTC1495018I2 (es) |
LU (1) | LU92759I2 (es) |
MX (1) | MXPA04010308A (es) |
MY (1) | MY144040A (es) |
NL (1) | NL300746I1 (es) |
NO (2) | NO330500B1 (es) |
NZ (2) | NZ575139A (es) |
PE (1) | PE20040412A1 (es) |
PL (1) | PL214718B1 (es) |
PT (2) | PT2065384E (es) |
RU (2) | RU2329264C9 (es) |
SG (1) | SG164279A1 (es) |
SI (2) | SI1495018T1 (es) |
TW (1) | TWI343919B (es) |
WO (1) | WO2003089428A1 (es) |
ZA (1) | ZA200408342B (es) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6346510B1 (en) | 1995-10-23 | 2002-02-12 | The Children's Medical Center Corporation | Therapeutic antiangiogenic endostatin compositions |
US7235567B2 (en) * | 2000-06-15 | 2007-06-26 | Schering Corporation | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist |
US20040192753A1 (en) * | 2000-06-15 | 2004-09-30 | Samuel Chackalamannil | Methods of use of thrombin receptor antagonists |
US7488742B2 (en) * | 2000-06-15 | 2009-02-10 | Schering Corporation | Thrombin receptor antagonists |
CN1984905B (zh) * | 2004-05-28 | 2011-06-22 | 先灵公司 | 作为凝血酶受体拮抗剂的约束喜巴辛类似物 |
JP2008515908A (ja) * | 2004-10-06 | 2008-05-15 | ユニバーシティー オブ ロチェスター | 組織因子経路を阻害する薬剤を使用する、肺高血圧症の治療 |
CA2594741A1 (en) * | 2005-01-14 | 2006-07-20 | Schering Corporation | Synthesis of himbacine analogs |
US7541471B2 (en) * | 2005-01-14 | 2009-06-02 | Schering Corporation | Synthesis of himbacine analogs |
US20060172397A1 (en) * | 2005-01-14 | 2006-08-03 | Schering Corporation | Preparation of chiral propargylic alcohol and ester intermediates of himbacine analogs |
AR056919A1 (es) * | 2005-01-14 | 2007-11-07 | Schering Corp | SíNTESIS EXO- Y DIASTEREO- SELECTIVAS DE ANÁLOGOS DE HIMBACINA |
CN101137636A (zh) * | 2005-01-14 | 2008-03-05 | 先灵公司 | Himbacine类似物的外型选择性合成 |
AU2006230292A1 (en) | 2005-03-31 | 2006-10-05 | Schering Corporation | Spirocyclic thrombin receptor antagonists |
US20070219154A1 (en) * | 2005-12-20 | 2007-09-20 | Suxing Liu | Methods for preventing and/or treating a cell proliferative disorder |
WO2007075964A2 (en) * | 2005-12-22 | 2007-07-05 | Schering Corporation | Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery |
TW200812619A (en) * | 2006-04-06 | 2008-03-16 | Schering Corp | TRA combination therapies |
CN101466704A (zh) | 2006-04-13 | 2009-06-24 | 先灵公司 | 稠合环凝血酶受体拮抗剂 |
MX2009000107A (es) * | 2006-06-29 | 2009-01-23 | Schering Corp | Antagonistas del receptor de trombina biciclicos y triciclicos sustituidos. |
AR061727A1 (es) * | 2006-06-30 | 2008-09-17 | Schering Corp | Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato |
TWI367112B (en) * | 2006-06-30 | 2012-07-01 | Schering Corp | Immediate-release tablet formulations of a thrombin receptor antagonist |
DE102006036023A1 (de) | 2006-08-02 | 2008-02-07 | Sanofi-Aventis | Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität |
TWI343262B (en) * | 2006-09-26 | 2011-06-11 | Schering Corp | Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist |
AU2007305269A1 (en) | 2006-10-04 | 2008-04-10 | Schering Corporation | Bicyclic and tricyclic derivatives as thrombin receptor antagonists |
KR20090058583A (ko) * | 2006-10-04 | 2009-06-09 | 쉐링 코포레이션 | 힘바신의 개질된 트리사이클릭 단위를 기본으로 하는 트롬빈 수용체 길항제 |
JP2010513516A (ja) * | 2006-12-22 | 2010-04-30 | シェーリング コーポレイション | 固形剤の湿式顆粒化処方物中の崩壊促進剤 |
US20080234236A1 (en) * | 2007-03-23 | 2008-09-25 | Veltri Enrico P | Reduction of adverse events after percutaneous intervention by use of a thrombin receptor antagonist |
CN101981034B (zh) | 2008-02-05 | 2013-08-14 | 赛诺菲-安万特 | 作为par1抑制剂的三唑并哒嗪、其制备及其制备药物的用途 |
RU2494100C2 (ru) | 2008-02-05 | 2013-09-27 | Санофи-Авентис | Соли триазолия в качестве ингибиторов par1, их получение и применение в качестве лекарственного средства |
WO2009124103A2 (en) * | 2008-04-02 | 2009-10-08 | Schering Corporation | Combination therapies comprising par1 antagonists with par4 antagonists |
EP2805939B1 (en) | 2008-05-19 | 2018-06-27 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as factor IXA inhibitors. |
EP2438060B1 (en) * | 2009-06-04 | 2013-10-02 | Merck Sharp & Dohme Corp. | Active metabolite of a thrombin receptor antagonist |
JP2012529431A (ja) | 2009-06-08 | 2012-11-22 | メルク・シャープ・アンド・ドーム・コーポレーション | トロンビン受容体アンタゴニストおよびクロピドグレルの固定用量錠剤 |
EP2462123B1 (en) | 2009-08-04 | 2013-10-02 | Merck Sharp & Dohme Corp. | 4,5,6-trisubstituted pyrimidine derivatives as factor ixa inhibitors |
WO2011128420A1 (de) | 2010-04-16 | 2011-10-20 | Sanofi | Pyridyl-vinyl-pyrazolo-chinoline als par1-inhibitoren |
PL2558465T3 (pl) | 2010-04-16 | 2015-05-29 | Sanofi Sa | Trycykliczne pirydylo-winylo-pirole jako inhibitory receptora aktywowanego proteazą 1 (PAR1) |
KR101303348B1 (ko) | 2010-06-25 | 2013-09-03 | 한국화학연구원 | 트롬빈 수용체 길항제인 [6+5]접합 바이사이클, 그의 제조방법 및 그를 포함하는 약제학적 조성물 |
US9340530B2 (en) | 2012-03-06 | 2016-05-17 | Merck Sharp & Dohme Corp. | Preparation and use of bicyclic himbacine derivatives as PAR-1 receptor antagonists |
WO2015013083A1 (en) * | 2013-07-22 | 2015-01-29 | Merck Sharp & Dohme Corp. | Co-crystal of the par-1 receptor antagonist vorapaxar and aspirin |
WO2015026685A1 (en) * | 2013-08-22 | 2015-02-26 | Merck Sharp & Dohme Corp. | 7a-heterocycle substituted- 6, 6-difluoro bicyclic himbacine derivatives |
EP3035928B1 (en) * | 2013-08-22 | 2023-10-18 | Merck Sharp & Dohme LLC | 3'-pyridyl substituted- 6,6-difluoro bicyclic himbacine derivatives |
EP3035929A4 (en) * | 2013-08-22 | 2017-03-15 | Merck Sharp & Dohme Corp. | 7a-amide substituted-6,6-difluoro bicyclic himbacine derivatives |
FR3014693B1 (fr) | 2013-12-16 | 2016-01-08 | Pf Medicament | Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales |
EP3131897B8 (en) | 2014-04-16 | 2022-08-03 | Merck Sharp & Dohme LLC | Factor ixa inhibitors |
DE102014108210A1 (de) | 2014-06-11 | 2015-12-17 | Dietrich Gulba | Rodentizid |
CN105985303B (zh) * | 2015-02-13 | 2020-08-14 | 上海彩迩文生化科技有限公司 | 抗凝血剂的制备方法、中间体及其制备方法 |
CN106478608A (zh) * | 2015-09-01 | 2017-03-08 | 博瑞生物医药(苏州)股份有限公司 | 沃拉帕沙的硫酸盐的结晶多晶型物 |
CN106749201A (zh) * | 2015-11-25 | 2017-05-31 | 博瑞生物医药(苏州)股份有限公司 | 一种沃拉帕沙及其中间体的制备方法 |
WO2017134200A1 (en) * | 2016-02-05 | 2017-08-10 | Sanovel Ilac Sanayi Ve Ticaret A.S. | A novel pharmaceutical composition of vorapaxar and metoprolol |
TR201601548A2 (tr) * | 2016-02-05 | 2018-03-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Vorapaksar ve metoprololün bi̇r farmasöti̇k kompozi̇syonu |
WO2017181993A1 (zh) * | 2016-04-22 | 2017-10-26 | 江苏天士力帝益药业有限公司 | 一种新的喜巴辛类似物及其在医药中的应用 |
CN106236779A (zh) * | 2016-08-22 | 2016-12-21 | 孔五 | 一种脐带血富血小板血浆prp的制备方法 |
FR3090317B1 (fr) | 2018-12-19 | 2021-05-07 | Cvasthera | Utilisation d’un antagoniste de par-1 pour le traitement d’une maladie inflammatoire chronique intestinale |
CN110407819B (zh) * | 2019-08-02 | 2020-06-26 | 牡丹江医学院 | 一种作为预防外科手术并发症的凝血酶受体拮抗剂 |
US20210113536A1 (en) * | 2019-10-21 | 2021-04-22 | United States Government as Represented by the Department of Veteran Affairs | Methods and compositions for detecting and treating venous thromboembolism |
FR3109089B1 (fr) | 2020-04-08 | 2023-04-14 | Cvasthera | Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales |
WO2022018156A1 (en) | 2020-07-22 | 2022-01-27 | Janssen Pharmaceutica Nv | Compounds useful as factor xia inhibitors |
US11919881B2 (en) | 2021-03-18 | 2024-03-05 | Janssen Pharmaceutica Nv | Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors |
US11814364B2 (en) | 2021-03-18 | 2023-11-14 | Janssen Pharmaceutica Nv | Pyridine N-oxide derivatives useful as factor XIa inhibitors |
US11845748B2 (en) | 2021-03-18 | 2023-12-19 | Janssen Pharmaceutica Nv | Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors |
EP4070658A1 (de) | 2021-04-06 | 2022-10-12 | BIORoxx GmbH | Verwendung von blutgerinnungshemmenden verbindungen als rodentizide |
US11897880B2 (en) | 2021-04-30 | 2024-02-13 | Janssen Pharmaceutica Nv | 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors |
US11958856B2 (en) | 2021-07-22 | 2024-04-16 | Janssen Pharmaceutica Nv | Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors |
FR3134314A1 (fr) | 2022-04-08 | 2023-10-13 | Cvasthera | Composition pharmaceutique à base de vorapaxar et son utilisation pour le traitement des maladies inflammatoires intestinales |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2623810B2 (fr) | 1987-02-17 | 1992-01-24 | Sanofi Sa | Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant |
IL106197A (en) | 1992-07-30 | 1999-11-30 | Cor Therapeutics Inc | Agagonists for the rhombin receptors and pharmaceutical preparations containing them |
US5576328A (en) | 1994-01-31 | 1996-11-19 | Elf Sanofi | Method for the secondary prevention of ischemic events |
SK285153B6 (sk) * | 1997-11-25 | 2006-07-07 | Schering Corporation | Heterocyklickou skupinou substituovaná tricyklická zlúčenina, farmaceutický prostriedok obsahujúci túto zlúčeninu a jej použitie |
US6063847A (en) | 1997-11-25 | 2000-05-16 | Schering Corporation | Thrombin receptor antagonists |
FR2779726B1 (fr) | 1998-06-15 | 2001-05-18 | Sanofi Sa | Forme polymorphe de l'hydrogenosulfate de clopidogrel |
HUP0303081A3 (en) * | 2000-06-15 | 2009-03-30 | Schering Corp | Thrombin receptor antagonists, pharmaceutical compositions containing them and their use |
US7488742B2 (en) | 2000-06-15 | 2009-02-10 | Schering Corporation | Thrombin receptor antagonists |
US20040192753A1 (en) | 2000-06-15 | 2004-09-30 | Samuel Chackalamannil | Methods of use of thrombin receptor antagonists |
BR0213967A (pt) | 2001-10-18 | 2005-08-30 | Schering Corp | Análogos de himbacina como antagonistas do receptor de trombina |
-
2003
- 2003-04-14 EP EP03718393A patent/EP1495018B3/en not_active Expired - Lifetime
- 2003-04-14 ES ES09150995T patent/ES2357876T3/es not_active Expired - Lifetime
- 2003-04-14 BR BRPI0309309A patent/BRPI0309309B8/pt not_active IP Right Cessation
- 2003-04-14 KR KR1020047016409A patent/KR101026929B1/ko active IP Right Grant
- 2003-04-14 US US10/412,982 patent/US7304078B2/en active Active
- 2003-04-14 SI SI200331110T patent/SI1495018T1/sl unknown
- 2003-04-14 CA CA2482858A patent/CA2482858C/en not_active Expired - Lifetime
- 2003-04-14 EP EP07016461A patent/EP1860106B1/en not_active Expired - Lifetime
- 2003-04-14 AT AT03718393T patent/ATE378330T1/de active
- 2003-04-14 PT PT09150995T patent/PT2065384E/pt unknown
- 2003-04-14 NZ NZ575139A patent/NZ575139A/en not_active IP Right Cessation
- 2003-04-14 EP EP08012015A patent/EP1982984B1/en not_active Expired - Lifetime
- 2003-04-14 AT AT07016461T patent/ATE455774T1/de not_active IP Right Cessation
- 2003-04-14 RU RU2004133375/04A patent/RU2329264C9/ru active
- 2003-04-14 MY MYPI20031400A patent/MY144040A/en unknown
- 2003-04-14 SI SI200331969T patent/SI2065384T1/sl unknown
- 2003-04-14 AR ARP030101302A patent/AR039570A1/es active IP Right Grant
- 2003-04-14 DE DE60317493.0T patent/DE60317493T3/de not_active Expired - Lifetime
- 2003-04-14 CN CN038131129A patent/CN1659162B/zh not_active Expired - Fee Related
- 2003-04-14 MX MXPA04010308A patent/MXPA04010308A/es active IP Right Grant
- 2003-04-14 ES ES07016461T patent/ES2338171T3/es not_active Expired - Lifetime
- 2003-04-14 JP JP2003586149A patent/JP4558331B2/ja not_active Expired - Fee Related
- 2003-04-14 WO PCT/US2003/011510 patent/WO2003089428A1/en active Application Filing
- 2003-04-14 AU AU2003221932A patent/AU2003221932B2/en not_active Ceased
- 2003-04-14 AT AT09150995T patent/ATE494284T1/de active
- 2003-04-14 PL PL373332A patent/PL214718B1/pl unknown
- 2003-04-14 SG SG200607217-7A patent/SG164279A1/en unknown
- 2003-04-14 ES ES03718393T patent/ES2297150T7/es active Active
- 2003-04-14 DE DE60331114T patent/DE60331114D1/de not_active Expired - Lifetime
- 2003-04-14 EP EP09150995A patent/EP2065384B1/en not_active Expired - Lifetime
- 2003-04-14 DE DE60335679T patent/DE60335679D1/de not_active Expired - Lifetime
- 2003-04-14 PT PT03718393T patent/PT1495018E/pt unknown
- 2003-04-14 EP EP09150996A patent/EP2062890B1/en not_active Expired - Lifetime
- 2003-04-14 NZ NZ535880A patent/NZ535880A/en not_active IP Right Cessation
- 2003-04-14 DK DK09150995.0T patent/DK2065384T3/da active
- 2003-04-14 DK DK03718393T patent/DK1495018T3/da active
- 2003-04-14 PE PE2003000375A patent/PE20040412A1/es active IP Right Grant
- 2003-04-15 TW TW092108648A patent/TWI343919B/zh not_active IP Right Cessation
-
2004
- 2004-10-14 ZA ZA200408342A patent/ZA200408342B/xx unknown
- 2004-10-14 IL IL164585A patent/IL164585A/en active IP Right Grant
- 2004-10-15 EC EC2004005368A patent/ECSP045368A/es unknown
- 2004-11-15 NO NO20044963A patent/NO330500B1/no not_active IP Right Cessation
-
2005
- 2005-04-22 HK HK05103479A patent/HK1070887A1/xx not_active IP Right Cessation
-
2007
- 2007-04-10 US US11/733,635 patent/US7713999B2/en active Active
- 2007-07-06 US US11/774,358 patent/US20070270439A1/en not_active Abandoned
-
2008
- 2008-02-07 CY CY20081100152T patent/CY1107184T1/el unknown
- 2008-02-21 RU RU2008106401/04A patent/RU2008106401A/ru not_active Application Discontinuation
-
2009
- 2009-03-23 HK HK09102736.6A patent/HK1123302A1/xx not_active IP Right Cessation
- 2009-09-14 HK HK09108388.4A patent/HK1129893A1/xx not_active IP Right Cessation
-
2010
- 2010-03-05 JP JP2010049903A patent/JP2010132710A/ja not_active Withdrawn
-
2011
- 2011-03-30 CY CY20111100338T patent/CY1111363T1/el unknown
-
2015
- 2015-06-29 NL NL300746C patent/NL300746I1/nl unknown
- 2015-06-29 LU LU92759C patent/LU92759I2/xx unknown
- 2015-07-01 LT LTPA2015027C patent/LTC1495018I2/lt unknown
- 2015-07-03 FR FR15C0047C patent/FR15C0047I2/fr active Active
- 2015-07-09 NO NO2015016C patent/NO2015016I1/no not_active IP Right Cessation
- 2015-07-10 CY CY2015029C patent/CY2015029I2/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LU92759I2 (en) | Vorapaxar ou son sel solvat pharmacologiquement admissible | |
IL165841A0 (en) | Mchir antagonists | |
GB0303210D0 (en) | Early entry | |
GB0403532D0 (en) | Early entry | |
EP1500622A4 (en) | LIFT WITHOUT MACHINE ROOM | |
AP2004003119A0 (en) | Substituted hydroxyethylamines | |
GB2395048B (en) | Interface devices | |
PL376509A1 (en) | Antagonists il-15 | |
GB0207015D0 (en) | Interface | |
GB0211257D0 (en) | Novel heterocycles | |
IL166740A0 (en) | Substituted heterocyclylpyrimidines | |
AU2003300904A8 (en) | Antagonists for human prolactin | |
SI1487778T1 (sl) | Substituirani 4-aminocikloheksanoli | |
EP1580045A4 (en) | UPPER FASTENING | |
GB0209608D0 (en) | Early entry | |
AU153894S (en) | Planer | |
GB0317960D0 (en) | Early entry | |
AU2003268504A8 (en) | Whale-safe rope | |
GB0414710D0 (en) | Thyristor | |
EP1512658A4 (en) | LIFT | |
IL162534A0 (en) | Novel alkansulfonamides as endotheline antagonists | |
GB0209989D0 (en) | Novel heterocycles | |
GB0215389D0 (en) | Receptor | |
GB0228658D0 (en) | Planer | |
PL377325A1 (pl) | Podstawione benzodioksepiny |